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Background: Cancer is a leading cause of death worldwide and its development is closely 
related to immune dysfunction. Immune checkpoint (IC) receptors maintain immune ho-
meostasis to protect normal tissues, but cancers use several immune escape mechanisms 
including altered IC expression to evade destruction by the immune system. Cytotoxic 
T-lymphocyte associated antigen-4 (CTLA-4) is one such IC, which downregulates T-cell 
activation. There are at least two isoforms of CTLA-4 in humans; the full-length receptor 
isoform and an alternatively spliced soluble CTLA-4 (sCTLA-4) isoform. The aim of this sys-
tematic review is to investigate whether or not human tumor cells express CTLA-4, and to 
examine if there are any consistent retrospective correlates of increased CTLA-4 expression 
with disease outcome. 
Methods: We searched Medline, Scopus, Embase and Web of science for original research 
articles that investigated CTLA-4 expression by human primary tumor cells or tumor cell 
lines, from 1987 to April 2020. Forty-five records were deemed eligible and data describing 
tumor site and stage, CTLA-4 isoform studied, test sample and control groups involved, 
methods and level (mRNA or protein) of detection, location and any retrospective associa-
tion with disease outcome were extracted.
Results: Of the forty-five eligible manuscripts, thirty-eight studies focused on the full-length 
isoform, one study focused on the soluble isoform and six studies investigated both. Forty-
two studies reported an increase in CTLA-4 detection by cancer cells. Twenty-one manu-
scripts performed a retrospective comparison of patient outcomes in CTLA-4 high and low 
groups in terms of overall survival; eleven studies found that high tumor CTLA-4 expres-
sion correlated with poor outcome while seven studies found an opposite correlation. Three 




Cancer is one of the leading causes of death 
worldwide, causing an estimated 9.96 mil-
lion deaths in 2020 [1]. The most common 
types of cancer include lung, breast, colorec-
tal, prostate, leukemia, lymphoma and skin 
cancers (carcinomas and melanomas). Lim-
itations of both cancer diagnosis and effective 
treatment place a colossal strain on those af-
fected, as well as healthcare budgets for mid-
dle- and low-income countries [2].
Our current understanding of how cancers 
develop points to an initial failure of immune 
surveillance and elimination of transforming 
cells, followed by an equilibrium period in 
which nascent cancer cells are kept in check 
by the immune system, and finally the evolu-
tion of molecular mechanisms that allow the 
cancer to evade the immune system to pro-
liferate and metastasize uncontrollably [3,4]. 
Cancer cells can escape detection by the im-
mune system through a number of potential 
mechanisms that can model the tumor micro-
environment to tolerate growth of the tumor. 
They can secrete immunosuppressive factors, 
such as TGF-β and IL-10 [5,6] or promote 
recruitment of immunosuppressive cells, such 
as regulatory CD4 T cells (Treg) [7] and my-
eloid-derived suppressor cells (MDSC) [8] to 
the tumor microenvironment. Intrinsically 
low or loss of MHC class I molecules also 
allow escape from detection [9]. Moreover, 
cancer cells can take advantage of immune 
checkpoints by usurping either directly or 
indirectly their function, including CTLA-4 
on regulatory T cells and programmed cell 
death-ligand 1 (PD-L1) on tumor cells, lead-
ing to dampening of the anti-tumor immune 
response [10,11]. Maintained high exposure 
to antigens in the tumor microenvironment, 
induces a state of dysfunction in anti-tumor 
effector T cells, called T cell exhaustion [12]. 
Exhausted T cells are terminally differentiat-
ed T Cells that lose their functionality and 
consequently fail to effectively eliminate can-
cer cells. They increasingly and sustainably 
express multiple inhibitory receptors, includ-
ing CTLA-4 and programmed cell death-1 
(PD-1) [13], which suppress their effector 
function.
The emergence of effective immunotherapy 
by antibody-mediated checkpoint blockade 
now offers new opportunities for improving 
patient outcomes in a range of cancers [14]. 
Immune checkpoints are typically surface 
receptors on T cells that aid in maintaining 
homeostasis, particularly during resolution of 
an immune response [15]. Unlike traditional 
cancer therapies that exhibit direct cytotoxic 
effects, e.g., chemotherapy and radiotherapy, 
blockade of immune checkpoints functions 
indirectly by boosting anti-tumor immunity 
[16].
Cytotoxic T-lymphocyte associated anti-
gen-4 (CTLA-4) or CD152 is a well-known 
immune cell checkpoint receptor. This full-
length receptor isoform, also called trans-
membrane CTLA-4 (tmCTLA-4), is consti-
tutively expressed in homodimeric form on 
the surface of regulatory T cells and activated 
effector T cells [17]. A second less well-known 
Conclusions: This review provides strong evidence that a variety of cancer cells express both 
CTLA-4 transcripts and functional CTLA-4, detectable in the cytoplasm or on the cell sur-
face. Overall, the data suggest that CTLA-4 expression levels in cancer cells are an important 
but variable feature of the disease phenotype, which will be both increasingly important 
to evaluate in the context of immune CI therapeutics, and may also be a useful response 
biomarker.
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isoform, soluble CTLA-4 (sCTLA-4), is 
secretable and produced by alternative 
mRNA splicing of the CTLA-4 gene [18,19].
Ipilimumab, a monoclonal anti-CTLA-4 
antibody and the first approved checkpoint 
inhibitor (CI), was approved for the treat-
ment of malignant melanoma in 2011 by 
the FDA [20]. Immunotherapy with an-
ti-CTLA-4 CI antibodies has been some-
what overshadowed by the emergence of 
anti-PD-1 and anti-PD-L1 antibodies that 
have seen much greater clinical and com-
mercial success [21,22]. These antibodies, 
first introduced in 2014, target PD-1 on an-
ti-tumor effector T cells or PD-L1 on tumor 
cells. Patient response frequency and stratifi-
cation are aided by PD-L1 staining levels on 
tumor biopsies [23]. Since their inception, 
the use of antibodies to inhibit the PD-1: 
PD-L1 axis has been approved for the treat-
ment of over 20 cancers including non-small 
cell lung cancer [24]. Anti-CTLA-4 antibod-
ies, in comparison to the anti-PD-1/PD-L1 
antibodies have received fewer FDA ap-
provals despite their potential to completely 
eradicate disease and provide an enduring 
remission from disease. Ipilimumab is cur-
rently approved as a monotherapy solely for 
melanoma but has also been partnered with 
nivolumab (anti-PD-1) for several cancers 
including advanced renal cell carcinoma 
[25], metastatic colorectal cancer, non-small 
cell lung cancer [26] and malignant pleural 
mesothelioma [27]. This has resulted in a sig-
nificant increase in the number of patients 
receiving long term survival benefits [28,29] 
compared with monotherapy. Therefore, it 
is now imperative to understand the role of 
anti-CTLA-4 therapy as well as CI therapy 
more broadly, particularly its effects on the 
tumor microenvironment including effector 
immune cell activation or regulatory T cell 
depletion in order to optimize treatment. 
Indeed, a combination of tumor intrinsic, 
immune cell specific and even tissue contex-
tual biomarkers may need to be combined in 
future bioassays to both stratify responsive 
patients and refine dosing strategies for an 
optimum outcome [30].
Although CTLA-4 is generally associated 
with immune cells, particularly T cells, it is 
also expressed by a number of non-immune 
cells including pituitary gland cells [31] and 
cancer cells [32]. The aim here was to survey 
and review systematically which tumors have 
been reported to express increased tumor cell 
levels of tmCTLA-4 or sCTLA-4 and further 
to determine whether patient outcome was 
influenced by the level of CTLA-4 expression 
by tumor cells.
METHODS
We conducted and reported this systemat-
ic review following the Preferred Reporting 
Items for Systematic Reviews and Meta-Anal-
yses (PRISMA) recommendations [33].
Search strategy 
A systematic search of Medline, Scopus, Em-
base, and Web of science biomedical and 
pharmacological databases of published liter-
ature from 1987 (discovery of CTLA-4 [17]) 
to April 2020 (date when search performed) 
was conducted. The search was restricted to 
studies published in the English language and 
studies conducted on humans and for stud-
ies related to the expression of CTLA-4 and/
or sCTLA-4 by cancer cells. The following 
keywords were used in our search strategy: 
(CTLA-4 OR sCTLA-4 OR “soluble CTLA-
4” OR CD152 OR tm?CTLA-4 OR “trans-
membrane CTLA-4” OR CTLA-4delTM 
OR “cytotoxic T lymphocyte associated 
protein?4” OR “soluble cytotoxic T lympho-
cyte associated protein?4” OR “cytotoxic T 
lymphocyte associated antigen?4” OR “sol-
uble cytotoxic T lymphocyte associated an-
tigen?4”) AND (cancer* OR malignan* OR 
tumor* OR tumor* OR neoplasm* OR “cell 
line”). The final search was performed on 11 
April 2020.
Our inclusion criteria were:
1. Original research articles
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2. Articles published in English
3. Studies assessing the expression of human 
full-length and/or soluble CTLA-4 by 
cancer cells
4. Studies conducted on human samples or 
human cell lines
Our exclusion criteria were:
1. Case reports, case studies, letters to the 
editor, conference abstracts, comments, 
review and systemic review articles
2. Studies conducted on animals
3. Studies assessing the expression of 
transmembrane and/or soluble CTLA-4 
in the tumor microenvironment including 
infiltrating lymphocytes
Duplicates were removed (based on au-
thors, title, journal, volume, issue and page 
numbers), using the referencing software 
Mendeley. Titles and abstracts were screened 
for potential relevance. 101 records were 
passed to the second stage (full-text screen-
ing) for further screening and data extraction. 
For these 101 entries, the full text of the ar-
ticles was obtained. In case of articles without 
full text, we searched for the relevant full‐text 
articles using the authors’ names and/or com-
binations of the title words or requested a full-
text from the authors. Full texts were subject-
ed to the inclusion and exclusion criteria listed 
above. All entries and full texts were evaluated 
independently by members of the study team; 
the senior author (FW) checked for accuracy 
and settled any cases of disagreement.
Data extraction
The studies which met the inclusion criteria 
were summarized and data extraction was 
performed independently by three investiga-
tors, using a pre-defined form and accuracy 
checks were performed by FA, RAE and FW. 
Data extracted included: First author, year 
of publication, sample size, control group, 
tumor site, clinical stage, study design, meth-
od of sample analysis, CTLA-4 isoform ana-
lyzed and association of CTLA-4 expression 
with tumor progression.
RESULTS
Manuscripts included in the 
systematic review
Of 4911 identified citations from the search 
results, we identified 101 articles which met 
the inclusion criteria by title and abstract 
screening. Most of the identified studies did 
not discriminate whether CTLA-4 was ex-
pressed/produced by the tumor cells or the 
microenvironment (immune cells), or if the 
studies only focused on CTLA-4 in immune 
cells. These studies therefore, had to be exclud-
ed as they did not meet the inclusion criteria. 
It was not possible to refine the search strategy 
to address this as this can be only identified 
upon screening the manuscripts. Following 
full text screening, 45 articles were deemed to 
be eligible for inclusion in this study. Figure 1 
shows the flow diagram of the studies retrieved 
for this systematic review. The characteristics 
of these studies are listed in Table 1 [32,34–77].
Manuscripts excluded from the 
systematic review
As illustrated in Figure 1, a total of 12,174 
results were obtained from the search from 
different databases. Following removing the 
duplicate, of the 4911 identified citations, we 
excluded 4810 articles that did not meet our 
inclusion criteria by title and abstract screening. 
Following full-text screening, 56 articles were 
excluded due to the reasons listed in Figure 1.
Data summary
The full characteristics of the study popu-
lations in the included manuscripts are dis-
played in Table 2.
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Samples & controls
All studies were conducted on human sam-
ples, either by extracting tumor cells and 
tissues by surgery from patients (n = 34), by 
using commercially available cancer cell lines 
(n = 5) or by both (n=6). 23 out of 45 studies 
included control groups, either tissues or cells 
from healthy volunteers or normal tissues 
adjacent to tumors from the same patients. 
However, the remaining 22 studies did not 
mention any information about including 
controls. Table 2 summarizes the study pop-
ulation and the control group.
Tumors expressing CTLA-4
The studies assessed CTLA-4 expression 
mainly in leukemia/lymphoma (n = 12) (two 
of the studies assessed the same cohort of 
CLL patients [36,37]), breast cancer (n = 7), 
lung cancer (n = 7) and melanoma (n = 6) 
while the remaining articles were about gas-
tric cancer (n = 3), esophageal (n = 2), uterine 
(n = 1), cervical (n = 2), ovarian (n = 1) and 
nasopharyngeal cancers (n = 2), thymoma (n 
= 1), mesothelioma (n = 1), testicular cancer 
(n = 1), salivary cystic carcinoma (n = 1), os-
teosarcoma (n = 1), rhabdomyosarcoma (n 
= 1), neuroblastoma (n = 1), renal (n = 1), 
colorectal (n = 1), bladder (n = 2) and bile 
duct cancers (n = 1). Figure 2 summarizes the 
different types of cancers that express CTLA-
4 which were reported in the manuscripts in-
cluded in our study.
Twelve included articles discussed the ex-
pression of CTLA-4 in leukemia/lympho-
ma. The subtypes of leukemia/lymphoma 
studied were: CML (n=1) [34], ALL (n=2) 
[34,42], AML (n=2) [34, 36], CLL (n=5) 
[34,45,47,48,67] with two studies assessing the 
same cohort ([47,48]), ATL (n=3) [35,39,77], 
CTCL (n=1) [37] and mantle cell lympho-
ma (n=1) [69]. All these studies showed that 
malignant cells express CTLA-4, apart from 
 f FIGURE 1
Flow diagram of the studies retrieved for the review.
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  f TABLE 1
Main characteristics of eligible studies.
Author Year Cancer subtype CTLA-4 isoform Studies conducted on mRNA 
or protein
Method for CTLA-4 detection CTLA-4 expression






Tm & s mRNA and protein IHC, Flow cytometry, RT-PCR, Western blot Expressed in 25–85% of AMLs and CMLs; positive expression in B-ALL, T-ALL and B-CLL; few 
negative cases in T-CLL
Contardi et al. [32] 2005 Colorectal adenocarcinoma Tm & s mRNA and protein Flow cytometry, RT-PCR Expressed in high levels in all the tested cell lines
Breast carcinoma IHC, flow cytometry, RT-PCR
Lung carcinoma Flow cytometry, RT-PCR
Ovarian carcinoma Flow cytometry, RT-PCR 
Uterine carcinoma Flow cytometry, RT-PCR 
Renal carcinoma Flow cytometry, RT-PCR 
Bladder carcinoma Flow cytometry, RT-PCR 
Neuroblastoma Flow cytometry, RT-PCR 
Rhabdomyosarcoma Flow cytometry, RT-PCR 
Melanoma Flow cytometry, RT-PCR 
Osteosarcoma IHC, Flow cytometry, RT-PCR, Western blot
Matsubara et al. [35] 2006 ATL Tm Protein Flow cytometry ATL cells from Foxp3-high cases expressed considerable levels, while those of Foxp3-low cases 
expressed no or very little CTLA-4
Laurent et al. [36] 2007 AML (M0-M7 subtypes) Tm & s mRNA and protein Flow cytometry, nested RT-PCR (semi 
quantitative)
Consistently expressed by leukemic blasts (M0, M1, M2 and M5 subtypes), although at different 
levels by flow cytometry, Extracellular domain detected while no full-length CTLA-4 detected by 
nested RT-PCR
Capriotti et al. [37] 2008 CTCL Tm mRNA qPCR Expressed in 21% of the samples
Shah et al. [38] 2008 Melanoma Tm & s mRNA & protein RT-PCR, RT- qPCR, Western blot, Flow 
cytometry
Positive expression
Shimauchi et al. [39] 2008 ATL Tm Protein IHC, Flow cytometry Elevated expression on 13.33% of the patients
Mao et al. [40] 2010 Breast cancer Tm mRNA & protein IHC and RT-PCR Strong expression in 100% of all the samples at both the protein and mRNA levels
Salvi et al. [41] 2012 NSCLC Tm Protein IHC Expression increased in 52.8% (non-squamous) and 35.7% squamous NSCLC
Simone et al. [42] 2012 ALL s mRNA and protein Flow cytometry, ELISA, Western blot, 
RT-PCR
Positive expression in 70% of B-ALL patients
Antczak et al. [43] 2013 NSCLC Tm mRNA q PCR Expression increased in 74.65% of the patients
Laurent et al. [44] 2013 Melanoma Tm & s mRNA & protein IHC, flow cytometry, ELISA, RT-PCR, qPCR Positively expressed in all the tested cell lines; sCTLA-4 transcript was expressed at lower levels 
than the full-length, in all cell lines except MECO
Mittal et al. [45] 2013 CLL Tm mRNA and protein Flow cytometry, RT-PCR (semi-quantita-
tive), qPCR, Western blot
Positively expressed; with CLL cells having different levels of expression (high CTLA-4 and low 
CTLA-4 expression)
Yu et al. [46] 2015 Breast cancer Tm & s Protein IHC Positively expressed
Ciszak et al. [47] 2016 CLL Tm Protein Flow cytometry Significantly higher levels expressed in patients compared to the controls
Ciszak et al. [48] 2016 CLL Tm Protein Flow cytometry Patients expressed significantly higher levels in comparison to the controls
Huang et al. [49] 2016 Nasopharyngeal carcinoma Tm Protein IHC Expressed with different intensities in 97.4% of the patients
Kim et al. [50] 2016 Gastric cancer Tm Protein IHC Positive expression in 65.8% of the patients
Roncella et al. [51] 2016 Mesothelioma Tm Protein IHC Expressed in 56% of the samples with variable intensity
Schloβer et al. [52] 2016 Gastric adenocarcinoma Tm Protein IHC, fluorescence microscopy, targeted 
sequence
Positive expression in 86% of the sample
Zhang et al. [53] 2016 Esophageal carcinoma Tm Protein IHC Expressed in 87% of the patients. Elevated CTLA-4 expression (“+” and “++”) was detected in 
52.6% of the samples expressing CLTA-4
Chakravarti et al. [54] 2017 Melanoma Tm  Protein IHC Highly expressed
Tm, Transmembrane (Full length) CTLA-4; s: Soluble CTLA-4; AML, Acute myeloid leukemia; ATL, Adult T cell leukemia; B-ALL, Acute lymphoblastic leukemia of B cell lineage; T-ALL, Acute lymphoblastic leukemia of T cell lineage; CLL, Chronic lymphocytic leukemia; CML, Chronic myeloid leukemia; EHBD, 
Extrahepatic bile duct cancer; ESCC, Esophageal squamous cell carcinoma; TGCTs, Testicular germ cell tumors; MCL, Mantle cell lymphoma; NSCLC, Non-small cell lung cancer; SCLC, Small cell lung cancer; MIBC, muscle-invasive bladder cancer; NMIBC non–muscle-invasive bladder cancer; N/A, Not available; IHC, 
Immunohistochemistry; PCR, Polymerase chain reaction; RT-PCR: reverse transcription PCR;  qPCR: quantitative real-time PCR; RT-qPCR: reverse transcription quantitative real-time PCR; ELISA, Enzyme-linked immunosorbent assay.
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Main characteristics of eligible studies.
Author Year Cancer subtype CTLA-4 isoform Studies conducted on mRNA 
or protein
Method for CTLA-4 detection CTLA-4 expression
Chen et al. [55] 2017 Breast cancer Tm Protein Flow cytometry Expressed by breast cancer cell lines, especially MDA-MB-231 and MCF-7
Le Goux et al. [56] 2017 Bladder urothelial 
carcinoma
Tm mRNA Real-time RT-qPCR CTLA-4 over-expressed in 84.5% in MIBC and in 35.2% in NMIBC samples
Karpathiou et al. [57] 2017 Laryngeal and pharyngeal 
squamous cell carcinoma
Tm Protein IHC Positive expression
Kim et al. [58] 2017 Breast cancer Tm mRNA Whole exome sequence, RNA-Seq, gene 
enrichment analysis 
Positive expression
Lafuente-Sanchis et al. 
[59]
2017 NSCLC Tm mRNA IHC, RT-qPCR Expression is detected in all the samples (100%)
Lim et al. [60] 2017 EHBD Tm Protein IHC Positive expression in 95% of the patients
Paulsen et al. [61] 2017 NSCLC Tm Protein IHC Over-expression in 50% stromal-CTLA-4 and 43% epithelial-CTLA-4
Yang et al. [62] 2017 Gastric cancer Tm Protein IHC, Western blot Positive expression in 43.7% of the sample by IHC
Kassardjian et al. [63] 2018 Breast cancer (ductal 
carcinoma in situ, invasive 
ductal carcinoma, invasive 
lobular carcinoma and inva-
sive tubular carcinoma)
Tm Protein IHC Over expressed in 52.7% of the all the samples with variation depending on tumor type and grade
Lan et al. [64] 2018 Breast cancer Tm Protein IHC Expressed in 41.2% of the samples
Mo et al. [65] 2018 Melanoma Tm mRNA and protein Confocal microscopy, flow cytometry, 
RT-qPCR, Western blot
Highly expressed by most human melanoma cell lines
Santoni et al. [66] 2018 Thymoma Tm mRNA and protein IHC, RT-qPCR, confocal microscopy CTLA-4 expression was statistically found to progressively increase in A, B1, B2, AB and it was 
maximal in B3 thymomas
Do et al. [67] 2019 CLL Tm mRNA and protein qPCR, flow cytometry, confocal microscopy CTLA-4 expression in CLL B-cells was one of the most differentially expressed genes, average 19-
fold change over normal B-cells (microarray); constitutive expression in CLL B cells compared to 
control (qPCR and confocal microscopy); constitutive intracellular expression in 61% patients (flow 
cytometry)
Gutiérrez-Hoya et al. 
[68]
2019 Cervical cancer Tm Protein Flow cytometry Positive expression
Harrington et al. [69] 2019 MCL Tm mRNA and protein qPCR, flow cytometry Very low mRNA expression
No Surface protein expression
Inozume et al. [70] 2019 Melanoma Tm mRNA and protein IHC, flow cytometry, confocal microscopy, 
RT-PCR
Expressed in 50% of tested the cell lines
Lobo et al. [71] 2019 TGCTs Tm Protein IHC Positive expression
Mosconi et al. [72] 2019 ACC of salivary gland Tm Protein IHC No expression
Regzedmaa et al. [73] 2019 SCLC Tm Protein IHC Expressed in 89.5% of the samples
Zhang et al. [74] 2019 ESCC Tm Protein IHC Elevated expression in 48.8% of the patients
Zhang et al. [75] 2019 NSCLC Tm Protein IHC, Western blot Expressed in high levels in A549, H460, HCC827 and H1975; very low levels in H661 and no 
detectable expression in H1650
Karpathiou et al. [76] 2020 uterine cervix cancer Tm Protein IHC Expression was found in 61.5 % of the invasive cases; CTLA-4 tumor cell expression was more 
often found in squamous cell carcinomas than in adenocarcinomas
Takeuchi et al. [77] 2020 ATL Tm Protein IHC No IHC stains with greater than 50% staining detected
Tm, Transmembrane (Full length) CTLA-4; s: Soluble CTLA-4; AML, Acute myeloid leukemia; ATL, Adult T cell leukemia; B-ALL, Acute lymphoblastic leukemia of B cell lineage; T-ALL, Acute lymphoblastic leukemia of T cell lineage; CLL, Chronic lymphocytic leukemia; CML, Chronic myeloid leukemia; EHBD, 
Extrahepatic bile duct cancer; ESCC, Esophageal squamous cell carcinoma; TGCTs, Testicular germ cell tumors; MCL, Mantle cell lymphoma; NSCLC, Non-small cell lung cancer; SCLC, Small cell lung cancer; MIBC, muscle-invasive bladder cancer; NMIBC non–muscle-invasive bladder cancer; N/A, Not available; IHC, 
Immunohistochemistry; PCR, Polymerase chain reaction; RT-PCR: reverse transcription PCR;  qPCR: quantitative real-time PCR; RT-qPCR: reverse transcription quantitative real-time PCR; ELISA, Enzyme-linked immunosorbent assay.
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Study population and control groups used in the included studies.
Author Cancer subtype Stage or grade Sample Control
Type Size (n) Type Size (n)






N/A Donor patients (Primary samples) and cell lines (CEM, Jurkat, Molt-4, Dau-
di, Raji, HOM-2, HL60, KG1a, K562)
100 patients and 9 cell lines Healthy donors 10
Contardi et al. (2005) 
[32]
Colorectal adenocarcino-
ma, breast carcinoma, lung 
carcinoma, ovarian carcino-





Grade 1 and grade 2 (breast carci-
noma), grade 4 (osteosarcoma), N/A 
(colorectal adenocarcinoma, lung, 
ovarian, uterine, renal and bladder 
carcinoma, neuroblastoma, rabdo-
myosarcoma and melanoma)
Donor patients (primary samples from osteosarcoma and breast cancer) 
and cell lines (4 colorectal adenocarcinoma cell lines: HCT-8, HT-29, COLO 
205 and CACO-2; 4 breast carcinoma cell lines: MCF-7, MDA-MB-231, 
T-47D, BT-20; 3 lung carcinoma cell lines: CALU-1, CALU-6, A549; 2 ovar-
ian carcinoma cell lines: SKOV-3 and A2780; 1 uterine carcinoma cell line; 
5 neuroblastoma cell lines: NB100, SJNKP, CHP212, SY5Y, SKNBE-2C; 3 
renal carcinoma cell lines: SKRC-10, SKRC-52, SKRC-59; 2 uterine carci-
noma cell lines: TG, HELA; 1 bladder carcinoma cell line: T24; 2 rabdomyo-
sarcoma cell lines: RD/18, TE671; 4 osteosarcoma cell lines, HOS, MG-63, 
U2-OS, SaOS-2; 3 melanoma cell lines, MEL-1, ALO-39, F0-1; 2 nontumor-
igenic human breast epithelial cell lines: MCF10A, HC11)
6 Osteosarcoma samples
5 breast cancer samples and
34 cell lines
PBMCs from healthy donors;
for osteosarcoma cell lines, 
HSSCs from healthy donors stim-
ulated to differentiate
toward the osteogenic lineage;
for breast tissue, non-malignant 




tissue adjacent to 
tumor
Matsubara et al. (2006) 
[35]
ATL I-IV Donor patients (primary samples) and cell lines (ATL-T,
ATL-2, ATL-43T, ATL-48T+, ATL-55T+,
ED-40515+, MT-1)
20 patients (9 patients of the
acute type, 10 of the chronic 
type, and 1 of the lymphoma
type) and
7 ATL derived cells lines
CD4+ and CDD4+CD25+ T cells 
purified from PBMCs from
healthy donors
N/A
Laurent et al. (2007) 
[36]
AML (M0-M7 subtypes) N/A Donor patients (primary samples) 25 (15 untreated and 10 che-
moresistant patients)
PBMCs from healthy donors N/A
Capriotti et al. (2008) 
[37]
CTCL I-III Donor patients (primary samples) 28 PBMCs from healthy donors 6
Shah et al. (2008) [38] Melanoma N/A Donor patients (primary samples) and cell lines (UACC 1273, A2058) N/A (patients) and
2 cell lines
N/A N/A
Shimauchi et al. (2008) 
[39]
ATL N/A Donor patients (primary samples) 21 PBMCs from healthy donors 8
Mao et al. (2010) [40] Breast cancer N/A Donor patients (primary samples) 60 Normal breast tissue from pa-
tients with benign breast
disease or external breast injury
30
Salvi et al. (2012) [41] NSCLC I–III Donor patients (primary samples) 81 Tumor-adjacent normal tissues N/A
Simone et al. (2012) [42] ALL N/A Donor pediatric patients (primary samples) 80 Age-matched normal serum sam-
ples from healthy donors
45
Antczak et al. (2013) 
[43]
NSCLC N/A Donor patients (primary samples) 71 (23 adenocarcinoma, 41 
squamous cell carcinoma and 7 
large cell carcinoma)
N/A N/A
Laurent et al. (2013) 
[44]
Melanoma N/A Donor patients (primary cell lines from metastatic lesions of cutaneous 
melanoma and melanoma tissue sections) and long term cell lines (C23, 
MeWo, FO-1)
14 primary cell lines, 3 long-
term cell lines and 
33 tissue sections
N/A N/A
Mittal et al. (2013) [45] CLL N/A Donor patients (primary samples including peripheral blood, bone marrow 
and lymph node samples)
105 N/A N/A
Yu et al. (2015) [46] Breast cancer I-III Donor patients (Primary samples) 130 N/A N/A
Ciszak et al. (2016) [47] CLL N/A Donor patients (primary samples) 38 B cells purified from healthy 
donor PBMCs
15
Ciszak et al. (2016) [48] CLL I–IV Donor patients (primary samples) 38 B cells purified from healthy 
donor PBMCs
6
Huang et al. (2016) [49] Nasopharyngeal carcinoma UICC I–IVc; WHO II & III Donor patients (primary samples) 191 N/A N/A
Kim et al. (2016) [50] Gastric cancer I–III Tissue microarrays from donor patients (primary samples) 243 Non-neoplastic gastric mucosa 
specimens 
N/A
n, number; N/A, not available; CLL, Chronic lymphocytic leukemia; ATL, Adult T-cell leukemia/lymphoma; PBMCs, Peripheral blood mononuclear cells; HSSCs, human stromal stem cells; MIBC, muscle-invasive bladder cancer; NMIBC non–muscle-invasive bladder cancer .
REVIEW 
  159DOI: 10.18609/ioi.2021.024 Immuno-Oncology Insights - ISSN 2634-5099 
IMMUNO-ONCOLOGY INSIGHTS 
  f TABLE 2 (CONT.)
Study population and control groups used in the included studies.
Author Cancer subtype Stage or grade Sample Control
Type Size (n) Type Size (n)
Schloβer et al. (2016) 
[52]
Gastric adenocarcinoma I-IV Donor patients (primary samples) 127 N/A N/A
Zhang et al. (2016) [53] Esophageal carcinoma I-IV Donor patients (primary samples) 158 N/A N/A
Chakravarti et al. (2017) 
[54]
Melanoma N/A Donor patients (primary samples) 81 N/A N/A
Chen et al. (2017) [55] Breast cancer N/A Cell lines (MDA-MB-231, SKBR3, MCF-7, T47D) 4 cell lines N/A N/A
Le Goux et al. (2017) 
[56]
Bladder urothelial carcinoma Ta-T3, low grade and high grade Donor patients (primary samples) 155 (84 with MIBC and 71 with 
NMIBC)
Normal bladder tissues from sur-
gery unrelated to bladder tumors
15
Karpathiou et al. (2017) 
[57]
Laryngeal and pharyngeal 
squamous cell carcinoma
I–IV Donor patients (primary samples) 152 N/A N/A
Kim et al.(2017) [58] Breast cancer Stage IV or recurrent after curative 
treatment
Donor patients (primary samples) 37 N/A N/A
Lafuente-Sanchis et al. 
(2017) [59]
NSCLC I–III Donor patients (primary samples) 78 Tumor-adjacent lung tissues 78
Lim et al. (2017) [60] EHBD T1–T4 Donor patients (primary samples) 77 N/A N/A
Paulsen et al. (2017) 
[61]
NSCLC I–IIIA Donor patients (primary samples) 536 N/A N/A
Yang et al. (2017) [62] Gastric cancer N/A Donor patients (primary samples) 48 Tumor-adjacent normal tissues 48
Kassardjian et al. (2018) 
[63]
Breast cancer (ductal carci-
noma in situ, invasive ductal 
carcinoma, invasive lobular 
carcinoma and invasive tubu-
lar carcinoma)
I–IV Commercially obtained breast tissue microarray sections 93 (73 invasive ductal, 10 inva-
sive lobular, 2 invasive tubular, 
8 ductal carcinoma in situ)
Normal breast tissues from the 
same tissue microarrays
6 (2 normal and 
4 with fibrocystic 
changes)
Lan et al. (2018) [64] Breast cancer I–III Donor patients (primary samples) 102 N/A N/A
Mo et al. (2018) [65] Melanoma N/A Cell lines (Hs 936.T, A2058, COLO679, WM983(B), 451 Lu, WM3918 and 
WM3912)
7 cell lines
(in addition to 61 melanoma 
cell lines from the cancer cell 
encyclopedia database)
Human primary neonatal foreskin 
melanocytes
N/A
Santoni et al. (2018) [66] Thymoma N/A Donor patients (primary samples) 68 PBMCs from healthy donors N/A
Do et al. (2019) [67] CLL 0–IV Donor patients (primary samples) and cell lines (Mec1, OSU-CLL) 28
N/A
B cells and T cells purified from 
blood from healthy donors
N/A
Gutiérrez-Hoya et al. 
(2019) [68]
Cervical cancer N/A Cell lines (HeLa (HPV 18), CaSki (HPV 16), C33A (HPV-), INBL) 4 cell lines N/A N/A
Harrington et al. (2019) 
[69]
MCL N/A Donor patients (primary samples) 16 PBMCs from healthy donors N/A
Inozume et al. (2019) 
[70]
Melanoma N/A Donor patients (primary samples)
Melanoma cell lines




Lobo et al. (2019) [71] TGCTs I–III Donor patients (primary cells) 271 tumour samples from 162 
patients
N/A N/A
Mosconi et al. (2019) 
[72]
ACC of salivary glands I–III Donor patients (primary samples) 36 N/A N/A
Regzedmaa et al. (2019) 
[73]
SCLC I-IV Donor patients (primary samples) 38 N/A N/A
Zhang et al. (2019) [74] ESCC I–IV Donor patients (primary samples) 84 N/A N/A
Zhang et al. (2019) [75] NSCLC N/A Cell lines (A549, H460, HCC827, H1975, H1650, H661) N/A N/A N/A
Karpathiou et al. (2020) 
[76]
Uterine cervix cancer 0–IV Donor patients (primary samples) 63 lesions from 52 patients N/A N/A
Takeuchi et al. (2020) 
[77]
ATL I–IV Donor patients (primary samples) 69 N/A N/A
n, number; N/A, not available; CLL, Chronic lymphocytic leukemia; ATL, Adult T-cell leukemia/lymphoma; PBMCs, Peripheral blood mononuclear cells; HSSCs, human stromal stem cells; MIBC, muscle-invasive bladder cancer; NMIBC non–muscle-invasive bladder cancer .
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2 studies, which stated that mantle cell lym-
phoma [69] and ATL [77] do not express 
CTLA-4, and this might be due to the small 
sample size [69] or the method used (only 
IHC was used) [77], in addition to the lack of 
control group [77].
A study that investigated the expression 
levels of CTLA-4 in adenoid cystic carcino-
ma of salivary gland founds that CTLA-4 ex-
pression in tumor cells is negative [72]. It is 
worth noting that only one method was used 
to assess protein expression (IHC).
On the other hand, we included seven 
studies about lung cancer which have clearly 
demonstrated positive expression of CTLA-
4 by cancer cells; the majority were focused 
on NSCLC (n=6) [32,41,43,59,61,75] with a 
single study on SCLC (n=1) [73].
Breast (n=7) [32,40,46,55,58,63,64], gas-
tric (n=3) [50,52,62] and melanoma (n=6) 
[32,38,44,54,65,70] cancer cells were con-
firmed for positive CTLA-4 expression by all 
the included manuscripts.
All the remaining types of cancers includ-
ed in this systematic review were positive for 
CTLA-4 expression. Expression patterns are 
summarized in Table 1.
In terms of cytoplasmic vs surface expres-
sion, twenty-two out of the forty-five stud-
ies looked at the intracellular localization 
of CTLA-4. One study examined only the 
cytoplasmic CTLA-4 [63] while the other 
twenty-one studies investigated both cyto-
plasmic and surface CTLA-4 levels, sixteen 
of them observed higher CTLA-4 levels in 
the cytoplasm than on the cell membrane 
[32,34,44,46–48,51,55,60–62,65,67,70,71,76], 
which is consistent with what we know about 
the endosomal/lysosomal vesicular localiza-
tion within cytoplasm previously reported 
in T cells, where CTLA-4 is rarely expressed 
on the membrane and is rapidly internalized 
into the cytoplasm by means of endocytosis 
[65]. The other five studies, however, did not 
specify where the highest levels of CTLA-4 
are localized [40,41,53,64,66].
 f FIGURE 2
Studies that reported detectable CTLA-4 in tumor cells.
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CTLA-4 isoform studied
With the exception of seven studies that in-
vestigated the soluble isoform of CTLA-4, 
either alone [42] or together with the full-
length isoform [32,34,36,38,44,46], the ma-
jority of the studies focused on the full-length 
isoform (n = 44). 
Methodologies used to detect 
CTLA-4 expression by cancer cells
As summarized in Table 1, CTLA-4 was 
detected either at the mRNA level (by re-
al-time PCR and/or RT-PCR) and/or at the 
protein level (by Western blotting, immuno-
histochemistry, flow cytometry, ELISA and/
or fluorescence microscopy). Most studies 
measured CTLA-4 at the protein level (n = 
27) [35,39,41,46–55,57,60–62,68,71–77] with 
two examining the same cohort [47,48] while 
four studies measured CTLA-4 only at the 
mRNA level [37,43,58,59]. Fourteen studies, 
however, measured CTLA-4 at both levels 
[32,34,36,38,40,42,44,45,56,65–67,69,70].
Correlation of CTLA-4 expression 
by tumor cells with clinical outcome
The outcomes of the studies analyzing the 
potentially prognostic role of CTLA-4 in 
cancers are varied, especially with regards 
to whether increased expression signifies a 
better or poorer outcome for the patient co-
hort (Figure 3). Out of the forty-five papers 
included in this study, twenty-one papers 
looked retrospectively at cancer progression 
including overall survival. In general, elev-
en studies found that high tumor CTLA-4 
expression correlated with poorer outcome 
compared with lower CTLA-4 expression 
[42,46,49,52–54,57,64,66,71,74]. Conversely, 
seven studies found an opposite correlation 
[42,45,47,51,60,61,73]. In mesothelioma, only 
the sCTLA-4 in the pleural effusion, rather 
than serum, was found to be a statistically sig-
nificant positive predictive factor [51]. Three 
studies, however, reported no association 
between tumor expression levels of CTLA-
4 and tumor progression [56,59,76]. Table 3 
illustrates the correlation between CTLA-4 
expression levels in cancer cells and disease 
outcome, in the twenty-one articles which 
reported that.
These observations led to the obvious 
question of whether or not any associations 
between patient outcome and CTLA-4 ex-
pression were specific to particular tumor 
types. Out of the twelve leukemia/lymphoma 
articles included in our review, only three in-
vestigated the association of tumor CTLA-4 
expression with patient clinical outcome. 
Two studies found that high tumor CTLA-4 
expression in CLL is a good prognostic factor 
[45,47]. Another study suggests that increased 
tumor sCTLA-4 expression in ALL cor-
relates with poor outcome [42]. Two studies 
by Ciszak et al. assessed the same cohort for 
CTLA-4 expression in CLL [47,48] and only 
one of them studied the correlation with dis-
ease progression [47].
In lung cancer, increased tumor CTLA-4 
expression was associated with better patient 
outcomes in three studies [61,73,78], includ-
ing one small cell lung cancer study [73]. One 
study found a diverging prognostic impact 
of CTLA-4 expression in metastatic NSCLC 
lymph nodes versus primary tumor; while 
high stromal CTLA-4 was a positive prog-
nostic factor in the squamous cell carcinoma 
(SCC) subgroup, no association with surviv-
al was found in the adenocarcinoma (ADC) 
and large cell carcinoma subgroups [61]. 
However, a study by Lafuente-Sanchis et al. 
demonstrated no association between tumor 
CTLA-4 expression levels and patient clinical 
outcomes [59].
Conversely, the two studies that examined 
the effect of increased CTLA-4 expression 
in breast cancer found a negative correlation 
with patient clinical outcome, suggesting that 
CTLA-4 might be a negative prognostic fac-
tor in breast cancer [46,64]. 
In esophageal carcinoma, increased tumor 
CTLA-4 expression is an independent pre-
dictor of shorter overall survival [53,74].
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Regarding gastric cancer, the prognostic ef-
fect of CTLA-4 was only studied in one article, 
which found a negative association between 
tumor CTLA-4 levels and overall survival [52].
In uterine cervix and bladder urothelial 
carcinoma, researchers could not find any 
correlation between CTLA-4 expression lev-
els and clinical outcome [56,76]. On the oth-
er hand, increased CTLA-4 tumor expression 
predicted longer overall survival in patients 
with mesothelioma [51] and EHDC [60], and 
shorter overall survival in patients with mel-
anoma [54], thymoma [66], nasopharyngeal 
carcinoma [49], testicular germ cell tumors 
[71] and laryngeal and pharyngeal squamous 
cell carcinoma [57]. However, we cannot 
build strong evidence collectively from these 
studies and more should be conducted to 
ascertain the relationship between CTLA-4 
expression in tumor cells, disease progression 
and patient outcomes. Furthermore, different 
methodologies were applied in the analysis 
of CTLA-4 in these studies, and at different 
levels (gene and/or protein) further compli-
cating a generalized conclusion.
DISCUSSION
One of the most important recent advances 
in cancer treatment has been the emergence 
of cancer immunotherapy, which is based on 
boosting the anti-tumor immune response 
rather than directly targeting tumor cells. De-
spite its impressive successes over the last de-
cade, in some patients the response is limited 
or short-lived and indeed, protocols that con-
sistently identify and stratify patients that will 
respond well to this type of therapy remain 
a high priority. These limited responses are 
mainly due to multiple tumor-mediated im-
mune escape mechanisms which tumor cells 
use to suppress anti-tumor immunity. One of 
the major and most important immune es-
cape mechanisms is by expressing co-inhib-
itory molecules, called immune checkpoints 
(IC). CTLA-4 in the context of the tumor 
microenvironment has typically been asso-
ciated with infiltrating T cells, not least in-
creased recruitment of regulatory T cells [79], 
but less attention has been paid to any role 
CTLA-4 may have when expressed by tumor 
cells directly. The clinical significance of the 
existence of this immunosuppressive mole-
cule in both tumor and immune cells within 
the tumor microenvironment remains to be 
fully elucidated, and its potential as a prog-
nostic marker or a therapeutic biomarker, in 
addition to any functional role it might have, 
needs to be further examined. 
In this systematic review, we assessed the 
body of available peer-reviewed literature 
 f FIGURE 3
Cancers in which relatively high expression levels of CTLA-4 correlate with disease outcome. 
REVIEW 
  163Immuno-Oncology Insights - ISSN 2634-5099  
regarding CTLA-4 expression, both tmCT-
LA-4 and sCTLA-4, by a wide variety of can-
cer subtypes with the aim of understanding its 
expression by tumors and its correlation with 
disease progression and clinical outcome. 
We found that the vast majority of stud-
ies demonstrated CTLA-4 expression was 
detectable, at the mRNA and/or protein 
levels, in tumor cells compared to its coun-
terpart healthy cells. Three studies, however, 
observed no CTLA-4 expression, although 
this might be because they only investigated 
its expression at the protein level using only 
one methodology, IHC [72,77], because of 
the small sample size [69] or because the type 
of the tumor cells they investigated might 
not express CTLA-4. In contrast, sCTLA-4 
was not studied as thoroughly as its counter-
part receptor; only seven studies investigated 
sCTLA-4 expression by cancer cells, but these 
studies confirmed the possibility that cancer 
cells secrete this naturally immunosuppres-
sive protein, perhaps as an immune evasion 
strategy [32,48–50].
Overall, this survey of CTLA-4 expres-
sion in tumor cells points to an area, which 
could yield a useful biomarker for CI therapy 
as part of the ongoing drive to generate pre-
dictable bioresponse profiles to treatment, 
but it also demands further comprehensive 
  f TABLE 3
The correlation of CTLA-4 expression levels in tumor cells (mRNA and/or protein) with the disease outcome.
Author Cancer subtype Studies conducted on 
mRNA or protein? 
Correlation of higher levels of tumor 
CTLA-4 with outcome
Salvi et al. (2012) [41] NSCLC Protein Good outcome
Simone et al. (2012) [42] ALL mRNA and protein Poor outcome
Mittal et al. (2013) [45] CLL mRNA and protein Good outcome (Low-CTLA-4 CLL was 
associated with poor outcome, while 
high-CTLA-4 CLL was associated with 
good outcome)
Yu et al. (2015) [46] Breast cancer Protein Poor outcome
Ciszak et al. (2016) [47] CLL Protein Good outcome
Huang et al. (2016) [49] Nasopharyngeal 
carcinoma
Protein Poor outcome
Roncella et al. (2016) [51] Mesothelioma Protein Good outcome
Schloβer et al. (2016) [52] Gastric 
adenocarcinoma
Protein Poor outcome
Zhang et al. (2016) [53] Esophageal carcinoma Protein Poor outcome
Chakravarti et al. (2017) 
[54]
Melanoma Protein Poor outcome
Le Goux et al. (2017) [56] Bladder urothelial 
carcinoma
mRNA and protein No correlation
Karpathiou et al. (2017) 
[57]
Laryngeal and pha-
ryngeal squamous cell 
carcinoma
Protein Poor outcome
Lafuente-Sanchis et al. 
(2017) [59]
NSCLC mRNA No correlation
Lim et al. (2017) [60] EHBD Protein Good outcome
Paulsen et al. (2017) [61] NSCLC Protein Good outcome
Lan et al. (2018) [64] Breast cancer Protein Poor outcome
Santoni et al. (2018) [66] Thymoma mRNA and protein Poor outcome
Lobo et al. (2019) [71] TGCTs Protein Poor outcome
Regzedmaa et al. (2019) 
[73]
SCLC Protein Good outcome
Zhang et al. (2019) [74] ESCC Protein Poor outcome
Karpathiou et al. (2020) 
[76]
Uterine cervix cancer Protein No correlation
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study. In particular, it will be useful to de-
finitively resolve the impact of high CTLA-
4 tumor cell levels both on patient outcome 
for each type of cancer and whether or not 
it affects CI therapy performance. Soluble 
CTLA-4 for instance, is bound by anti-CT-
LA-4 antibodies such that high serum levels 
of this immunosuppressive molecule could 
affect the amount of antibody engaging 
with tmCTLA-4. Moreover, our data sug-
gest that antibodies specific for CTLA-4 ex-
pressed by T cells could also target cancer 
cells directly. 
We looked for any correlation between 
CTLA-4 levels, disease progression and pa-
tient outcome in this study. Eleven studies 
found that high tumor CTLA-4 expression 
correlated with disease progression while low-
er CTLA-4 expression correlated with better 
outcomes [42,46,49,52–54,57,64,66,71,73]. 
Conversely, seven studies found an opposite 
correlation, where high CTLA-4 expres-
sion correlated with better clinical outcomes 
[45,47,51,60,61,73,78]. Three studies, howev-
er, reported no association between tumor 
expression levels of CTLA-4 and tumor pro-
gression [56,59,76]. The data from these stud-
ies are not robust enough to define clearly 
why these differences in outcome exist, but it 
is interesting to note that the cancers in which 
a worse outcome was observed do not over-
lap with those with a better outcome (Figure 
3). This suggests that increased CTLA-4 ex-
pression has different, yet to be determined, 
effects in different types of cancer. Other rea-
sons might be differences in methods used for 
CTLA-4 detection and whether it was at an 
mRNA or protein level. Additionally, there 
is a significant variation in the assessment of 
different CTLA-4 isoforms with sCTLA-4 
being understudied.
Accordingly, we suggest a more robust 
streamlined protocol to assess CTLA-4 ex-
pression in tumors and its correlation with 
disease progression and clinical outcome.
Another possible biomarker could be the 
secretable sCTLA-4, which has not received 
the same level of examination in terms of im-
mune regulation that its receptor counterpart 
has over the years and any role it might play 
particularly with regard to cancer progression 
is still unclear. Interestingly, it has been pre-
viously shown that selective blockade of sCT-
LA‐4 exhibited a stronger and more consis-
tent, significant enhancing effect on Ag‐driven 
PBMC responses than pan‐specific blockade 
of total CTLA‐4 [80]. However, most of the 
studies included in this review which inves-
tigated sCTLA-4 expression used the ELI-
SA assay method to measure serum levels 
[40,42,44,51] or pleural effusion [51], which 
does not discriminate whether  it is produced 
and secreted by cancer cells or immune cells. 
This emphasizes the need to further study the 
expression of the soluble isoform by different 
tumor cell types with selective antibodies, as 
well as the need to use more than one method 
to detect its expression and to study its role in 
cancer and how cancer cells potentially use it 
to escape the immune system.
TRANSLATIONAL INSIGHT
Taken together, data from this systematic 
review provide evidence that CTLA-4 is ex-
pressed not only by immune cells but also 
by many types of cancer cells. Further, the 
data emphasize the importance of assessing 
the correlation between CTLA-4 levels and a 
patient’s clinical outcome by using a more ro-
bust streamlined protocol to assess CTLA-4 
levels in cancer cells, together with correlating 
both mRNA and protein levels with the dis-
ease progression. Moreover, there are only few 
studies which investigated the expression of 
the soluble CTLA-4 isoform by cancer cells, 
which means that the role of this key mol-
ecule might be underestimated, and further 
studies should be conducted to understand 
its role and function in cancer. Therefore, 
our findings suggest the need to define better 
and more robust methods to detect soluble 
CTLA-4 expression by tumor cells, in a wide 
variety of tumor types, and to deeply study its 
role in immune cells as well as in cancer cells. 
Checkpoint inhibitor antibodies represent 
a novel type of cancer immunotherapy that 
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has proven obvious success in the treatment 
of different cancers. As one of the major tar-
gets of checkpoint inhibitors, CTLA-4 needs 
to be studied more thoroughly in regards of 
its expression by cancer cells to assess its full 
potential, not only as a therapeutic target, 
but also as a biomarker for patient stratifi-
cation, predicting prognosis and response to 
therapy within a broader set of biomarkers, 
which help to delineate the tumor microenvi-
ronment as a prelude to CI therapy. Despite 
the huge clinical benefits that CTLA-4 of-
fers in both cancer and autoimmune disease 
immunotherapy, its role and function espe-
cially in non-immune cells remains largely 
unexplored.
REFERENCES
1. Ferlay J, Colombet M, Soerjomataram I 
et al. Cancer statistics for the year 2020: 
An overview. Int. J. Cancer 2021.
2. Sung H, Ferlay J, Siegel RL et al. Global 
Cancer Statistics 2020: GLOBOCAN 
Estimates of Incidence and Mortali-
ty Worldwide for 36 Cancers in 185 
Countries. CA Cancer J. Clin. 2021; 71: 
209–49.
3. Dunn GP, Old LJ, Schreiber RD. The 
three Es of cancer immunoediting. Annu. 
Rev. Immunol. 2004; 22: 329–60.
4. Mittal D, Gubin MM, Schreiber RD, 
Smyth MJ. New insights into cancer 
immunoediting and its three component 
phases--elimination, equilibrium and 
escape. Curr. Opin. Immunol. 2014; 27: 
16–25.
5. Dalal BI, Keown PA, Greenberg AH. 
Immunocytochemical localization of 
secreted transforming growth factor-beta 
1 to the advancing edges of primary 
tumors and to lymph node metastases 
of human mammary carcinoma. Am. J. 
Pathol. 1993; 143: 381–9.
6. Gastl GA, Abrams JS, Nanus DM et al. 
Interleukin-10 production by human 
carcinoma cell lines and its relationship 
to interleukin-6 expression. Int. J. Cancer 
1993; 55: 96–101.
7. Facciabene A, Motz GT, Coukos G. 
T-regulatory cells: key players in tumor 
immune escape and angiogenesis. Cancer 
Res. 2012; 72: 2162–71.
8. OuYang LY, Wu XJ, Ye SB et al. Tu-
mor-induced myeloid-derived suppres-
sor cells promote tumor progression 
through oxidative metabolism in human 
colorectal cancer. J. Transl. Med. 2015; 
13: 47–015.
9. Dhatchinamoorthy K, Colbert JD, Rock 
KL. Cancer Immune Evasion Through 
Loss of MHC Class I Antigen Presenta-
tion. Front. Immunol. 2021; 12: 636568.
10. Thompson RH, Dong H, Lohse CM et 
al. PD-1 is expressed by tumor-infiltrat-
ing immune cells and is associated with 
poor outcome for patients with renal cell 
carcinoma. Clin. Cancer Res. 2007; 13: 
1757–61.
11. Dong H, Strome SE, Salomao DR et 
al. Tumor-associated B7-H1 promotes 
T-cell apoptosis: a potential mechanism 
of immune evasion. Nat. Med. 2002; 8: 
793–800.
12. Wherry EJ, Kurachi M. Molecular and 
cellular insights into T cell exhaustion. 
Nat. Rev. Immunol. 2015; 15: 486–99.
13. Wherry EJ, Ha SJ, Kaech SM et al. 
Molecular signature of CD8+ T cell 
exhaustion during chronic viral infection. 
Immunity 2007; 27: 670–84.
14. Leach DR, Krummel MF, Allison JP. 
Enhancement of antitumor immunity 
by CTLA-4 blockade. Science 1996; 271: 
1734–6.
15. Mellman I, Coukos G, Dranoff G. Can-
cer immunotherapy comes of age. Nature 
2011; 480: 480–9.
16. Sharma P, Allison JP. The future of im-
mune checkpoint therapy. Science 2015; 
348: 56–61.
17. Brunet JF, Denizot F, Luciani MF et al. 
A new member of the immunoglobulin 
superfamily--CTLA-4. Nature 2022; 
328: 267–70.
18. Magistrelli G, Jeannin P, Herbault N et 
al. A soluble form of CTLA-4 generated 
by alternative splicing is expressed by 
nonstimulated human T cells. Eur. J. 
Immunol. 1999; 29: 3596–602.
19. Oaks MK, Hallett KM, Penwell RT, 
Stauber EC, Warren SJ, Tector AJ. A 
native soluble form of CTLA-4. Cell 
Immunol. 2000; 201: 144–53.
20. Hodi FS, O’Day SJ, McDermott DF et 
al. Improved survival with ipilimumab in 
patients with metastatic melanoma. N. 
Engl. J. Med. 2010; 363: 711–23.
21. Robert C, Schachter J, Long GV et al. 
Pembrolizumab versus Ipilimumab in 
Advanced Melanoma. N. Engl. J. Med. 
2015; 372: 2521–32.
22. Weber JS, D’Angelo SP, Minor D et 
al. Nivolumab versus chemotherapy in 
patients with advanced melanoma who 
progressed after anti-CTLA-4 treat-
ment (CheckMate 037): a randomised, 
166 DOI: 10.18609/ioi.2021.024
IMMUNO-ONCOLOGY INSIGHTS 
controlled, open-label, phase 3 trial. 
Lancet Oncol. 2015; 16: 375–84.
23. Lantuejoul S, Sound-Tsao M, Cooper 
WA et al. PD-L1 Testing for Lung Can-
cer in 2019: Perspective From the IASLC 
Pathology Committee. J. Thorac. Oncol. 
2020; 15: 499–519.
24. Ward FJ, Dahal LN, Abu-Eid R. On the 
Road to Immunotherapy-Prospects for 
Treating Head and Neck Cancers With 
Checkpoint Inhibitor Antibodies. Front. 
Immunol. 2018; 9: 2182.
25. Motzer RJ, Tannir NM, McDermott 
DF et al. Nivolumab plus Ipilimumab 
versus Sunitinib in Advanced Renal-Cell 
Carcinoma. N. Engl. J. Med. 2018; 378: 
1277–90.
26. Reck M, Ciuleanu TE, Lee JS et al. First-
Line Nivolumab Plus Ipilimumab Versus 
Chemotherapy in Advanced NSCLC 
With 1% or Greater Tumor PD-L1 
Expression: Patient-Reported Outcomes 
From CheckMate 227 Part 1. J. Thorac. 
Oncol. 2021; 16: 665–76.
27. Baas P, Scherpereel A, Nowak AK et al. 
First-line nivolumab plus ipilimumab in 
unresectable malignant pleural mesothe-
lioma (CheckMate 743): a multicentre, 
randomised, open-label, phase 3 trial. 
Lancet 2021; 397: 375–86.
28. Larkin J, Chiarion-Sileni V, Gonzalez R 
et al. Five-Year Survival with Combined 
Nivolumab and Ipilimumab in Advanced 
Melanoma. N. Engl. J. Med. 2019; 381: 
1535–46.
29. Motzer RJ, Escudier B, McDermott DF 
et al. Survival outcomes and independent 
response assessment with nivolumab plus 
ipilimumab versus sunitinib in patients 
with advanced renal cell carcinoma: 
42-month follow-up of a randomized 
phase 3 clinical trial. J. Immunother. 
Cancer 2020; 8: 10.1136/jitc-2020.
30. Sharma P, Siddiqui BA, Anandhan S et 
al. The Next Decade of Immune Check-
point Therapy. Cancer Discov. 2021; 11: 
838–57.
31. Iwama S, De Remigis A, Callahan MK, 
Slovin SF, Wolchok JD, Caturegli P. 
Pituitary expression of CTLA-4 mediates 
hypophysitis secondary to administra-
tion of CTLA-4 blocking antibody. Sci. 
Transl. Med. 2014; 6: 230ra45.
32. Contardi E, Palmisano GL, Tazzari PL 
et al. CTLA-4 is constitutively expressed 
on tumor cells and can trigger apoptosis 
upon ligand interaction. Int. J. Cancer 
2005; 117: 538–50.
33. Liberati A, Altman DG, Tetzlaff J et al. 
The PRISMA statement for reporting 
systematic reviews and meta-analyses of 
studies that evaluate healthcare interven-
tions: explanation and elaboration. BMJ 
2009; 339: b2700.
34. Pistillo MP, Tazzari PL, Palmisano GL 
et al. CTLA-4 is not restricted to the 
lymphoid cell lineage and can function as 
a target molecule for apoptosis induc-
tion of leukemic cells. Blood 2003; 101: 
202–9.
35. Matsubar Y, Hori T, Morita R, Sakaguchi 
S, Uchiyama T. Delineation of immu-
noregulatory properties of adult T-cell 
leukemia cells. Int. J. Hematol. 2006; 84: 
63–9.
36. Laurent S, Palmisano GL, Martelli AM et 
al. CTLA-4 expressed by chemoresistant, 
as well as untreated, myeloid leukae-
mia cells can be targeted with ligands 
to induce apoptosis. Br. J. Haematol. 
2007;136:597-608.
37. Capriotti E, Vonderheid EC, Thoburn 
CJ, Wasik MA, Bahler DW, Hess AD. 
Expression of T-plastin, FoxP3 and other 
tumor-associated markers by leukemic 
T-cells of cutaneous T-cell lymphoma. 
Leuk. Lymphoma 2008; 49: 1190–201.
38. Shah KV, Chien AJ, Yee C, Moon RT. 
CTLA-4 is a direct target of Wnt/
beta-catenin signaling and is expressed 
in human melanoma tumors. J. Invest 
.Dermatol. 2008; 128: 2870–9.
39. Shimauchi T, Kabashima K, Tokura Y. 
Adult T-cell leukemia/lymphoma cells 
from blood and skin tumors express cyto-
toxic T lymphocyte-associated antigen-4 
and Foxp3 but lack suppressor activity 
toward autologous CD8+ T cells. Cancer 
Sci. 2008; 99: 98–106.
40. Mao H, Zhang L, Yang Y et al. New 
insights of CTLA-4 into its biological 
function in breast cancer. Curr. Cancer 
Drug Targets 2010; 10: 728–36.
41. Salvi S, Fontana V, Boccardo S et al. 
Evaluation of CTLA-4 expression and 
relevance as a novel prognostic factor in 
patients with non-small cell lung cancer. 
Cancer Immunol. Immunother. 2012; 61: 
1463–72.
42. Simone R, Tenca C, Fais F et al. A solu-
ble form of CTLA-4 is present in paedi-
atric patients with acute lymphoblastic 
leukaemia and correlates with CD1d+ 
expression. PLoS One 2012; 7: e44654.
43. Antczak A, Pastuszak-Lewandoska D, 
Gorski P et al. Ctla-4 expression and 
polymorphisms in lung tissue of patients 
with diagnosed non-small-cell lung 
cancer. Biomed. Res. Int. 2013; 2013: 
576486.
44. Laurent S, Queirolo P, Boero S et al. The 
engagement of CTLA-4 on primary mel-
anoma cell lines induces antibody-depen-
dent cellular cytotoxicity and TNF-alpha 
production. J. Transl. Med. 2013; 11: 
108–5876.
45. Mittal AK, Chaturvedi NK, Rohlfsen RA 
et al. Role of CTLA4 in the proliferation 
and survival of chronic lymphocytic 
leukemia. PLoS One 2013; 8: e70352.
REVIEW 
  167Immuno-Oncology Insights - ISSN 2634-5099  
46. Yu H, Yang J, Jiao S, Li Y, Zhang W, 
Wang J. Cytotoxic T lymphocyte antigen 
4 expression in human breast cancer: im-
plications for prognosis. Cancer Immunol. 
Immunother. 2015; 64: 853–60.
47. Ciszak L, Frydecka I, Wolowiec D, 
Szteblich A, Kosmaczewska A. Patients 
with chronic lymphocytic leukaemia 
(CLL) differ in the pattern of CTLA-4 
expression on CLL cells: the possible 
implications for immunotherapy with 
CTLA-4 blocking antibody. Tumour 
Biol. 2016; 37: 4143–57.
48. Ciszak L, Frydecka I, Wolowiec D, 
Szteblich A, Kosmaczewska A. CTLA-
4 affects expression of key cell cycle 
regulators of G0/G1 phase in neoplastic 
lymphocytes from patients with chronic 
lymphocytic leukaemia. Clin. Exp. Med. 
2016; 16: 317–32.
49. Huang PY, Guo SS, Zhang Y et al. 
Tumor CTLA-4 overexpression predicts 
poor survival in patients with nasopha-
ryngeal carcinoma. Oncotarget. 2016; 7: 
13060–8.
50. Kim JW, Nam KH, Ahn SH et al. 
Prognostic implications of immunosup-
pressive protein expression in tumors as 
well as immune cell infiltration within 
the tumor microenvironment in gastric 
cancer. Gastric Cancer 2016; 19: 42–52.
51. Roncella S, Laurent S, Fontana V et 
al. CTLA-4 in mesothelioma patients: 
tissue expression, body fluid levels and 
possible relevance as a prognostic factor. 
Cancer Immunol. Immunother. 2016; 65: 
909–17.
52. Schlosser HA, Drebber U, Kloth M et al. 
Immune checkpoints programmed death 
1 ligand 1 and cytotoxic T lymphocyte 
associated molecule 4 in gastric adeno-
carcinoma. Oncoimmunology 2015; 5: 
e1100789.
53. Zhang XF, Pan K, Weng DS et al. Cyto-
toxic T lymphocyte antigen-4 expression 
in esophageal carcinoma: implications for 
prognosis. Oncotarget. 2016; 7: 26670–9.
54. Chakravarti N, Ivan D, Trinh VA et al. 
High cytotoxic T-lymphocyte-associated 
antigen 4 and phospho-Akt expression 
in tumor samples predicts poor clinical 
outcomes in ipilimumab-treated mela-
noma patients. Melanoma Res. 2017; 27: 
24–31.
55. Chen X, Shao Q, Hao S et al. CTLA-
4 positive breast cancer cells suppress 
dendritic cells maturation and function. 
Oncotarget. 2017; 8: 13703–15.
56. Le Goux C, Damotte D, Vacher S et al. 
Correlation between messenger RNA 
expression and protein expression of 
immune checkpoint-associated mole-
cules in bladder urothelial carcinoma: A 
retrospective study. Urol. Oncol. 2017; 
35: 257–63.
57. Karpathiou G, Casteillo F, Giroult JB et 
al. Prognostic impact of immune micro-
environment in laryngeal and pharyngeal 
squamous cell carcinoma: Immune cell 
subtypes, immuno-suppressive pathways 
and clinicopathologic characteristics. 
Oncotarget. 2017; 8: 19310–22.
58. Kim JY, Lee E, Park K et al. Immune 
signature of metastatic breast cancer: 
Identifying predictive markers of immu-
notherapy response. Oncotarget. 2017; 8: 
47400–11.
59. Lafuente-Sanchis A, Zuniga A, Estors M 
et al. Association of PD-1, PD-L1, and 
CTLA-4 Gene Expression and Clini-
copathologic Characteristics in Patients 
With Non-Small-Cell Lung Cancer. 
Clin. Lung Cancer 2017; 18: e109-16.
60. Lim YJ, Koh J, Kim K et al. Clinical 
Implications of Cytotoxic T Lymphocyte 
Antigen-4 Expression on Tumor Cells 
and Tumor-Infiltrating Lymphocytes in 
Extrahepatic Bile Duct Cancer Patients 
Undergoing Surgery Plus Adjuvant 
Chemoradiotherapy. Target Oncol. 2017; 
12: 211–8.
61. Paulsen EE, Kilvaer TK, Rakaee M et 
al. CTLA-4 expression in the non-small 
cell lung cancer patient tumor microen-
vironment: diverging prognostic impact 
in primary tumors and lymph node 
metastases. Cancer Immunol Immunother. 
2017; 66: 1449–61.
62. Yang X, Lv T, Qiang J et al. Expression 
and significance of CD28, CTLA-4, 
CD80 AND CD86 in gastric cancer. 
Biomedical Research (India) 2007; 28(22): 
10159–64.
63. Kassardjian A, Shintaku PI, Moatamed 
NA. Expression of immune checkpoint 
regulators, cytotoxic T lymphocyte 
antigen 4 (CTLA-4) and programmed 
death-ligand 1 (PD-L1), in female 
breast carcinomas. PLoS One 2018; 
13:e0195958.
64. Lan G, Li J, Wen Q et al. Cytotoxic T 
lymphocyte associated antigen 4 expres-
sion predicts poor prognosis in luminal 
B HER2-negative breast cancer. Oncol. 
Lett. 2018; 15: 5093–7.
65. Mo X, Zhang H, Preston S et al. Interfer-
on-gamma Signaling in Melanocytes and 
Melanoma Cells Regulates Expression of 
CTLA-4. Cancer Res. 2018; 78: 436–50.
66. Santoni G, Amantini C, Morelli MB et 
al. High CTLA-4 expression correlates 
with poor prognosis in thymoma pa-
tients. Oncotarget. 2018; 9: 16665–77.
67. Do P, Beckwith KA, Cheney C et al. 
Leukemic B Cell CTLA-4 Suppresses 
Costimulation of T Cells. J. Immunol. 
2019; 202: 2806–16.
68. Gutierrez-Hoya A, Zerecero-Carreon O, 
Valle-Mendiola A et al. Cervical Cancer 
Cells Express Markers Associated with 




69. Harrington BK, Wheeler E, Hornbuckle 
K et al. Modulation of immune check-
point molecule expression in mantle cell 
lymphoma. Leuk. Lymphoma 2019; 60: 
2498–507.
70. Inozume T, Hanada KI, Takeda K, Mae-
da T, Harada K, Kawamura T. Cytotoxic 
T-lymphocyte-associated protein 4 ex-
pressed by melanoma cells does not affect 
melanoma-specific cytotoxic T lympho-
cytes in the effector phase. J. Dermatol. 
2019; 46: 52–6.
71. Lobo J, Rodrigues A, Guimaraes R et al. 
Detailed Characterization of Immune 
Cell Infiltrate and Expression of Immune 
Checkpoint Molecules PD-L1/CTLA-4 
and MMR Proteins in Testicular Germ 
Cell Tumors Disclose Novel Disease 
Biomarkers. Cancers (Basel) 2019; 11: 
10.3390/cancers11101535.
72. Mosconi C, de Arruda JAA, de Farias 
ACR et al. Immune microenvironment 
and evasion mechanisms in adenoid 
cystic carcinomas of salivary glands. Oral 
Oncol. 2019; 88: 95–101.
73. Regzedmaa O, Li Y, Li Y et al. Preva-
lence of DLL3, CTLA-4 and MSTN 
Expression in Patients with Small Cell 
Lung Cancer. Onco Targets Ther. 2019; 
12: 10043–55.
74. Zhang CY, Zhang J, Ma YF, Zhe H, 
Zhao R, Wang YY. Prognostic Value of 
Combined Analysis of CTLA-4 and PLR 
in Esophageal Squamous Cell Carcinoma 
(ESCC) Patients. Dis. Markers 2019; 
2019: 1601072.
75. Zhang H, Dutta P, Liu J et al. Tumour 
cell-intrinsic CTLA4 regulates PD-L1 
expression in non-small cell lung cancer. 
J. Cell Mol. Med. 2019; 23: 535–42.
76. Karpathiou G, Chauleur C, Mobarki 
M, Peoc’h M. The immune checkpoints 
CTLA-4 and PD-L1 in carcinomas of 
the uterine cervix. Pathol. Res. Pract. 
2020; 216: 152782.
77. Takeuchi M, Miyoshi H, Nakashima K 
et al. Comprehensive immunohistochem-
ical analysis of immune checkpoint mole-
cules in adult T cell leukemia/lymphoma. 
Ann. Hematol. 2020; 99: 1093–8.
78. Salvi S, Fontana V, Boccardo S et al. 
Evaluation of CTLA-4 expression and 
relevance as a novel prognostic factor in 
patients with non-small cell lung cancer. 
Cancer Immunol. Immunother. 2012; 61: 
1463–72.
79. Campbell DJ. Control of Regulatory T 
Cell Migration, Function, and Homeo-
stasis. J. Immunol. 2015; 195: 2507–13.
80. Ward FJ, Dahal LN, Wijesekera SK et 
al. The soluble isoform of CTLA-4 as 
a regulator of T-cell responses. Eur. J. 
Immunol. 2013; 43: 1274–85.
81. combined drugs. Ann. Appl. Stat. 2011; 
5(2A): 924–42.
82. Takeda K, Taguri M, Morita S. BOIN‐
ET: Bayesian optimal interval design 
for dose finding based on both efficacy 
and toxicity outcomes. Pharmaceut. Stat. 
2018; 17(4): 383–95.
83. Guo B, Li Y, Yuan Y. A dose–schedule 
finding design for phase I–II clinical 
trials. J R Stat. Soc. Ser. C Appl. Stat. 
2016;65(2):259-272.
84. Jin I, Liu S, Thall PF, Yuan Y. Using Data 
Augmentation to Facilitate Conduct of 
Phase I–II Clinical Trials With Delayed 
Outcomes. J. Am. Stat. Assoc. 2014; 
109(506): 525–36.
85. Liu S, Guo B, Yuan Y. A Bayesian Phase 
I/II Trial Design for Immunotherapy. 




Equally contributing first author 
Institute of Medical Sciences, Univer-
sity of Aberdeen, UK
Niss Larossi 
Equally contributing first author 
Institute of Medical Sciences, Univer-
sity of Aberdeen, UK 
and 
Institute of Biological Sciences, Uni-
versity of Manchester, UK
Okanda Ogbonda 
Equally contributing first author 
Institute of Medical Sciences, Univer-
sity of Aberdeen, UK 
Rasha Abu-Eid 
Co-corresponding author 
Institute of Medical Sciences, Univer-
sity of Aberdeen, UK 
and 
Institute of Dentistry, University of 
Aberdeen, UK 
rasha.abueid@abdn.ac.uk
Frank James Ward 
Co-corresponding author 
Institute of Medical Sciences, Univer-
sity of Aberdeen, UK 
mmd475@abdn.ac.uk
REVIEW 
  169Immuno-Oncology Insights - ISSN 2634-5099  
AUTHORSHIP & CONFLICT OF INTEREST
Contributions: Farah Abdulkhaleq, Niss Larossi and Okanda Ogbonda performed the search, screening and data extraction. Farah 
Abdulkhaleq, Rasha Abu-Eid and Frank James Ward wrote and edited the manuscript. Rasha Abu-Eid and Frank James Ward designed 
the study and checked the accuracy of data extraction.
Acknowledgements: Farah Abdulkhaleq is supported by an Elphinstone Scholarship from the University of Aberdeen.
Disclosure and potential conflicts of interest: The authors declare that they have no conflicts of interest.
Funding declaration: The authors received no financial support for the research, authorship and/or publication of this article. 
ARTICLE & COPYRIGHT INFORMATION
Copyright: Published by Immuno-Oncology Insights under Creative Commons License Deed CC BY NC ND 4.0 which allows anyone to 
copy, distribute, and transmit the article provided it is properly attributed in the manner specified below. No commercial use without 
permission.
Attribution: Copyright © 2021 Abdulkhaleq F, Larossi N, Ogbonda O, Abu-Eid R & Ward FJ. Published by Immuno-Oncology Insights 
under Creative Commons License Deed CC BY NC ND 4.0.
Article source: Invited; externally peer reviewed.
Submitted for peer review: May 20 2021; Revised manuscript received: Jun 17 2021; Publication date: Jun 24 2021.
